Trials / Completed
CompletedNCT04923464
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
A Phase 4 Decentralized Pilot Study With Wearable Technology in Cystic Fibrosis Subjects 18 Years of Age and Older Taking Commercial Elexacaftor/Tezacaftor/Ivacaftor
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 51 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the performance of wearable technology in cystic fibrosis (CF) participants taking commercial Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) utilizing a fully decentralized trial design.
Conditions
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2021-12-20
- Completion
- 2021-12-20
- First posted
- 2021-06-11
- Last updated
- 2022-01-19
Locations
17 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT04923464. Inclusion in this directory is not an endorsement.